新しく診断されたフィラデルフィア染色体陽性の急性リンパ芽球性白血病患者の治療におけるメシル酸イマチニブと併用化学療法
フィラデルフィアでの染色体陽性の急性リンパ芽球性白血病 (Ph+ALL) の国際第 3 相試験で、2 つの異なる細胞傷害性化学療法のバックボーンと組み合わせたイマチニブをテスト
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemotherapy regimen may work as well as the stronger one but have fewer side effects when given with imatinib. The trial is also testing how well the combination of chemotherapy and imatinib works in another group of patients with a type of ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+ ALL, is thought it will respond well to the combination of agents used to treat Ph+ ALL.
調査の概要
状態
介入・治療
- 他の:Laboratory Biomarker Analysis
- 薬:Cyclophosphamide
- 薬:Doxorubicin
- 薬:Vincristine Sulfate
- 他の:Questionnaire Administration
- 薬:Daunorubicin Hydrochloride
- 薬:Etoposide
- 薬:Mercaptopurine
- 薬:Methylprednisolone
- 薬:Ifosfamide
- 薬:Calaspargase Pegol
- 薬:Leucovorin Calcium
- 薬:Methotrexate
- 薬:Cytarabine
- 薬:Dexamethasone
- 薬:Dexrazoxane Hydrochloride
- 生物学的:Filgrastim
- 薬:Imatinib Mesylate
- 薬:Levoleucovorin
- 薬:Pegaspargase
- 薬:Prednisolone
- 薬:Therapeutic Hydrocortisone
- 薬:Thioguanine
- 手順:Allogeneic Hematopoietic Stem Cell Transplantation
詳細な説明
PRIMARY OBJECTIVE:
I. To compare disease-free survival (DFS) of standard risk (SR) pediatric Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) treated with continuous imatinib mesylate (imatinib) combined with either a high-risk Children's Oncology Group (COG) ALL chemotherapy backbone or the more intensive European (Es)PhALL chemotherapy backbone.
SECONDARY OBJECTIVES:
I. To compare DFS of SR pediatric Ph+ and ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.
II. To determine the feasibility of administration of imatinib after allogeneic hematopoietic stem cell transplantation (HSCT) in high risk (HR) Ph+ ALL patients.
III. To determine event-free survival (EFS) of HR pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission and post-HSCT imatinib.
IV. To compare rates of grade 3 or higher infections in standard risk (SR) Ph+ ALL patients between the two randomized arms.
V. To evaluate EFS and overall survival (OS) of all eligible Ph+ALL patients enrolled on the study.
VI. To evaluate OS in SR Ph+ ALL patients. VII. To evaluate OS in HR Ph+ ALL patients. VIII. To evaluate EFS and OS of all eligible ABL-class fusion positive ALL patients enrolled on the study.
EXPLORATORY OBJECTIVES:
I. To describe the toxicities associated with post-HSCT administration of imatinib in HR Ph+ALL patients.
II. To evaluate the long-term toxicities in SR Ph+ ALL patients treated with chemotherapy plus imatinib (no transplant), overall and between both randomized arms.
III. To determine prognostic significance of minimal residual disease (MRD) in Ph+ ALL at various time points during therapy.
IIIa. To evaluate MRD in HR patients just prior to HSCT and then at regular intervals post-HSCT and explore the association of these measurements with long-term outcome.
IIIb. To evaluate concordance of MRD assessments made by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) assay and next generation sequencing (NGS) assays.
IV. To determine and validate if IKZF1 deletions alone (IKZF1del) or with other transcription factor deletions (ie, IKZF1 plus subtype [IKZF1plus]) or other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.
V. To determine the frequency and prognostic significance of p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL.
VI. To measure adherence to oral chemotherapeutic agents (imatinib, 6-mercaptopurine and methotrexate) during the maintenance phase in SR Ph+ ALL patients.
VIa. To identify factors associated with poor adherence. VIb. To determine association between relapse risk and adherence to each oral chemotherapeutic agent (separately and combined).
VII. To measure adherence to imatinib after allogeneic HSCT in HR Ph+ ALL patients and identify factors associated with poor adherence.
VIII. To compare DFS of SR ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.
IX. Other secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients.
X. Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable and feasible, will be evaluated in the super set of Ph+ and ABL-class fusion positive ALL patients.
XI. To determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events and to test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft (PDX) models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631.
XII. To decipher the molecular and cellular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays and investigate CML-like phenotypes via single-cell ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions.
OUTLINE:
INDUCTION IA PART 1: Patients receive induction IA according to standard of care on days 1-14.
INDUCTION IA PART 2: Patients receive imatinib mesylate orally (PO) once daily (QD) or twice daily (BID) on days 15-33, prednisolone PO twice daily (BID) or methylprednisolone intravenously (IV) on days 15-28, vincristine sulfate IV over 1 minute on days 15 and 22, daunorubicin hydrochloride IV over 1-15 minutes on days 15 and 22, and methotrexate intrathecally (IT) on day 29.
INDUCTION IB: Patients receive imatinib mesylate PO QD or BID on days 1-35, cyclophosphamide IV over 30-60 minutes on days 1 and 28, mercaptopurine PO on days 1-28, cytarabine IV or subcutaneously (SC) on days 3-6, 10-13, 17-20, and 24-27, and methotrexate IT on days 10 and 24.
POST-INDUCTION THERAPY: Patients classified as standard risk are randomized to 1 of 2 arms. Patients with high risk are assigned to Arm C.
ARM A (SR patients assigned to ARM A):
CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 6, dexamethasone PO BID or IV on days 1-5, cyclophosphamide IV over 30-60 minutes on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, high dose cytarabine IV over 3 hours and pegaspargase or calaspargase pegol IV over 1-2 hours on day 5, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, dexamethasone PO BID or IV on days 1-5, vincristine sulfate IV over 1 minute on days 1 and 6, ifosfamide IV over 1 hour on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, dexrazoxane hydrochloride IV over 15 minutes and daunorubicin hydrochloride IV over 1-15 minutes on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate PO QD or BID on days 1-21, high dose cytarabine IV over 3 hours on days 1-3, dexamethasone PO BID or IV on days 1-5, etoposide IV over 1-2 hours on days 3-5, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 1 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 1 PART 2: Patients receive imatinib mesylate PO QD on days 36-63, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 38-41 and 45-48, and methotrexate IT on days 38 and 45in the absence of disease progression or unexpected toxicity.
INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate PO on days 1, 8, 15, and 22, and mercaptopurine PO on days 1-28 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 2 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 2 PART 2: Patients receive imatinib mesylate PO QD on days 36-49, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 36-39 and 43-46, and methotrexate IT on days 36 and 43 in the absence of disease progression or unexpected toxicity.
MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, methotrexate PO once weekly (QW) and IT on days 1 and 43 of cycles 1, 2, and 3, and mercaptopurine PO on days 1-84. Cycles with imatinib mesylate and mercaptopurine repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.
ARM B (SR PATIENTS ASSIGNED TO ARM B):
INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-63, vincristine sulfate IV over 1 minute and high dose methotrexate IV over 24 hours on days 1, 15, 29, and 43, leucovorin calcium or levoleucovorin PO or IV on days 3-4, 17-18, 31-32, and 45-46, mercaptopurine PO on days 1-56, and methotrexate IT on days 1 and 29 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 1, 8, and 15, and pegaspargase or calaspargase pegol IV over 1-2 hours or IM on day 4 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION PART 2: Patients receive imatinib mesylate PO QD on days 29-56, cyclophosphamide IV over 30-60 minutes on day 29, thioguanine PO on days 29-42, cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39, methotrexate IT on days 29 and 36, vincristine sulfate IV over 1 minute on days 43 and 50, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 43 in the absence of disease progression or unexpected toxicity.
INTERIM MAINTENANCE WITH CAPIZZI METHOTREXATE: Patients receive imatinib mesylate PO QD or BID on days 1-56, vincristine sulfate IV over 1 minute and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41, methotrexate IT on days 1 and 31, and pegaspargase or calaspargase pegol IV over 1-2 hours on days 2 and 23 in the absence of disease progression or unexpected toxicity.
MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, vincristine sulfate IV over 1 minute on days 1, 29, and 57, prednisolone PO BID (or methylprednisolone IV for cycle 1 and 2) on days 1-5, 29-33, and 57-61, mercaptopurine PO on days 1-84, methotrexate PO QW, and methotrexate IT on day 1 (and day 29 for cycle 1 and 2). Cycles repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.
ARM C (HR PATIENTS):
CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, vincristine sulfate, dexamethasone, leucovorin calcium or levoleucovorin, high dose cytarabine, and pegaspargase or calaspargase pegol as in Arm A Consolidation Block 1, and filgrastim SC or IV on day 7 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, dexamethasone, vincristine sulfate, ifosfamide, leucovorin calcium or levoleucovorin, dexrazoxane hydrochloride, daunorubicin hydrochloride, pegaspargase or calaspargase pegol, and filgrastim as Arm A Consolidation Block 2 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate, dexamethasone, etoposide, methotrexate, cytarabine, therapeutic hydrocortisone, pegaspargase or calaspargase pegol, and filgrastim as in Arm A Consolidation Block 3, and high dose cytarabine IV over 3 hours on days 1-2 in the absence of disease progression or unexpected toxicity.
HSCT: Patients undergo HSCT on day 0. Patients who do not proceed to HSCT receive Delayed Intensification 1, Interim Maintenance, Delayed Intensification 2, and Maintenance as in Arm A.
POST-HSCT: Patients receive imatinib mesylate PO QD or BID starting on days 56-365 in the in the absence of disease progression or unexpected toxicity.
After completion of study treatment, patients are followed up every year for 3 years.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- Children's Hospital of Alabama
-
Mobile、Alabama、アメリカ、36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage、Alaska、アメリカ、99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa、Arizona、アメリカ、85202
- Banner Children's at Desert
-
Phoenix、Arizona、アメリカ、85016
- Phoenix Childrens Hospital
-
Tucson、Arizona、アメリカ、85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey、California、アメリカ、90242
- Kaiser Permanente Downey Medical Center
-
Duarte、California、アメリカ、91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda、California、アメリカ、92354
- Loma Linda University Medical Center
-
Long Beach、California、アメリカ、90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles、California、アメリカ、90048
- Cedars-Sinai Medical Center
-
Los Angeles、California、アメリカ、90027
- Children's Hospital Los Angeles
-
Madera、California、アメリカ、93636
- Valley Children's Hospital
-
Oakland、California、アメリカ、94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland、California、アメリカ、94611
- Kaiser Permanente-Oakland
-
Orange、California、アメリカ、92868
- Children's Hospital of Orange County
-
Palo Alto、California、アメリカ、94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento、California、アメリカ、95817
- University of California Davis Comprehensive Cancer Center
-
San Diego、California、アメリカ、92123
- Rady Children's Hospital - San Diego
-
San Francisco、California、アメリカ、94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- Children's Hospital Colorado
-
Denver、Colorado、アメリカ、80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06106
- Connecticut Children's Medical Center
-
New Haven、Connecticut、アメリカ、06520
- Yale University
-
-
Delaware
-
Wilmington、Delaware、アメリカ、19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- Children's National Medical Center
-
Washington D.C.、District of Columbia、アメリカ、20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Lauderdale、Florida、アメリカ、33316
- Broward Health Medical Center
-
Fort Myers、Florida、アメリカ、33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville、Florida、アメリカ、32610
- UF Health Cancer Institute - Gainesville
-
Hollywood、Florida、アメリカ、33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville、Florida、アメリカ、32207
- Nemours Children's Clinic-Jacksonville
-
Loxahatchee Groves、Florida、アメリカ、33470
- Palms West Radiation Therapy
-
Miami、Florida、アメリカ、33155
- Nicklaus Children's Hospital
-
Miami、Florida、アメリカ、33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami、Florida、アメリカ、33176
- Miami Cancer Institute
-
Orlando、Florida、アメリカ、32827
- Nemours Children's Hospital
-
Orlando、Florida、アメリカ、32803
- AdventHealth Orlando
-
Orlando、Florida、アメリカ、32806
- Arnold Palmer Hospital for Children
-
Pensacola、Florida、アメリカ、32504
- Sacred Heart Hospital
-
St. Petersburg、Florida、アメリカ、33701
- Johns Hopkins All Children's Hospital
-
Tampa、Florida、アメリカ、33606
- Tampa General Hospital
-
Tampa、Florida、アメリカ、33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach、Florida、アメリカ、33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Augusta、Georgia、アメリカ、30912
- Augusta University Medical Center
-
Macon、Georgia、アメリカ、31201
- Atrium Health Navicent
-
Savannah、Georgia、アメリカ、31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise、Idaho、アメリカ、83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Comprehensive Cancer Center
-
Chicago、Illinois、アメリカ、60612
- University of Illinois
-
Chicago、Illinois、アメリカ、60611
- Lurie Children's Hospital-Chicago
-
Oak Lawn、Illinois、アメリカ、60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge、Illinois、アメリカ、60068
- Advocate Children's Hospital-Park Ridge
-
Peoria、Illinois、アメリカ、61637
- OSF Children's Hospital of Illinois
-
Springfield、Illinois、アメリカ、62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Riley Hospital for Children
-
Indianapolis、Indiana、アメリカ、46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines、Iowa、アメリカ、50309
- Blank Children's Hospital
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- University of Kentucky/Markey Cancer Center
-
Louisville、Kentucky、アメリカ、40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor、Maine、アメリカ、04401
- Eastern Maine Medical Center
-
Scarborough、Maine、アメリカ、04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore、Maryland、アメリカ、21215
- Sinai Hospital of Baltimore
-
Bethesda、Maryland、アメリカ、20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana-Farber Cancer Institute
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital Cancer Center
-
Boston、Massachusetts、アメリカ、02111
- Tufts Children's Hospital
-
Worcester、Massachusetts、アメリカ、01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- C S Mott Children's Hospital
-
Detroit、Michigan、アメリカ、48201
- Children's Hospital of Michigan
-
Detroit、Michigan、アメリカ、48236
- Henry Ford Health Saint John Hospital
-
East Lansing、Michigan、アメリカ、48823
- Michigan State University
-
Grand Rapids、Michigan、アメリカ、49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo、Michigan、アメリカ、49007
- Bronson Methodist Hospital
-
Royal Oak、Michigan、アメリカ、48073
- Corewell Health Children's
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis、Minnesota、アメリカ、55455
- University of Minnesota/Masonic Cancer Center
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia、Missouri、アメリカ、65212
- University of Missouri Children's Hospital
-
Kansas City、Missouri、アメリカ、64108
- Children's Mercy Hospitals and Clinics
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63141
- Mercy Hospital Saint Louis
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68198
- University of Nebraska Medical Center
-
Omaha、Nebraska、アメリカ、68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89144
- Summerlin Hospital Medical Center
-
Las Vegas、Nevada、アメリカ、89109
- Sunrise Hospital and Medical Center
-
Las Vegas、Nevada、アメリカ、89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas、Nevada、アメリカ、89102
- University Medical Center of Southern Nevada
-
Reno、Nevada、アメリカ、89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University Medical Center
-
Morristown、New Jersey、アメリカ、07960
- Morristown Medical Center
-
Neptune City、New Jersey、アメリカ、07753
- Jersey Shore Medical Center
-
New Brunswick、New Jersey、アメリカ、08901
- Saint Peter's University Hospital
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark、New Jersey、アメリカ、07112
- Newark Beth Israel Medical Center
-
Paterson、New Jersey、アメリカ、07503
- Saint Joseph's Regional Medical Center
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- Presbyterian Hospital
-
Albuquerque、New Mexico、アメリカ、87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany、New York、アメリカ、12208
- Albany Medical Center
-
Brooklyn、New York、アメリカ、11219
- Maimonides Medical Center
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
Mineola、New York、アメリカ、11501
- NYU Langone Hospital - Long Island
-
New Hyde Park、New York、アメリカ、11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
New York、New York、アメリカ、10029
- Mount Sinai Hospital
-
New York、New York、アメリカ、10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York、New York、アメリカ、10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester、New York、アメリカ、14642
- University of Rochester
-
Stony Brook、New York、アメリカ、11794
- Stony Brook University Medical Center
-
Syracuse、New York、アメリカ、13210
- State University of New York Upstate Medical University
-
The Bronx、New York、アメリカ、10467
- Montefiore Medical Center - Moses Campus
-
Valhalla、New York、アメリカ、10595
- New York Medical College
-
-
North Carolina
-
Asheville、North Carolina、アメリカ、28801
- Mission Hospital
-
Chapel Hill、North Carolina、アメリカ、27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte、North Carolina、アメリカ、28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte、North Carolina、アメリカ、28204
- Novant Health Presbyterian Medical Center
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
Greenville、North Carolina、アメリカ、27834
- East Carolina University
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron、Ohio、アメリカ、44308
- Children's Hospital Medical Center of Akron
-
Cincinnati、Ohio、アメリカ、45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
Cleveland、Ohio、アメリカ、44106
- Rainbow Babies and Childrens Hospital
-
Columbus、Ohio、アメリカ、43205
- Nationwide Children's Hospital
-
Dayton、Ohio、アメリカ、45404
- Dayton Children's Hospital
-
Toledo、Ohio、アメリカ、43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- Oregon Health and Science University
-
Portland、Oregon、アメリカ、97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville、Pennsylvania、アメリカ、17822
- Geisinger Medical Center
-
Hershey、Pennsylvania、アメリカ、17033
- Penn State Children's Hospital
-
Philadelphia、Pennsylvania、アメリカ、19104
- Children's Hospital of Philadelphia
-
Philadelphia、Pennsylvania、アメリカ、19134
- Saint Christopher's Hospital for Children
-
Pittsburgh、Pennsylvania、アメリカ、15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
Columbia、South Carolina、アメリカ、29203
- Prisma Health Richland Hospital
-
Greenville、South Carolina、アメリカ、29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37403
- T C Thompson Children's Hospital
-
Knoxville、Tennessee、アメリカ、37916
- East Tennessee Childrens Hospital
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville、Tennessee、アメリカ、37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Amarillo、Texas、アメリカ、79106
- Texas Tech University Health Sciences Center-Amarillo
-
Austin、Texas、アメリカ、78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi、Texas、アメリカ、78411
- Driscoll Children's Hospital
-
Dallas、Texas、アメリカ、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas、Texas、アメリカ、75230
- Medical City Dallas Hospital
-
El Paso、Texas、アメリカ、79905
- El Paso Children's Hospital
-
Fort Worth、Texas、アメリカ、76104
- Cook Children's Medical Center
-
Houston、Texas、アメリカ、77030
- UT MD Anderson Cancer Center
-
Houston、Texas、アメリカ、77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock、Texas、アメリカ、79410
- Covenant Children's Hospital
-
Lubbock、Texas、アメリカ、79415
- UMC Cancer Center / UMC Health System
-
San Antonio、Texas、アメリカ、78207
- Children's Hospital of San Antonio
-
San Antonio、Texas、アメリカ、78229
- Methodist Children's Hospital of South Texas
-
Temple、Texas、アメリカ、76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84113
- Primary Children's Hospital
-
-
Vermont
-
Burlington、Vermont、アメリカ、05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- University of Virginia Cancer Center
-
Falls Church、Virginia、アメリカ、22042
- Inova Fairfax Hospital
-
Norfolk、Virginia、アメリカ、23507
- Children's Hospital of The King's Daughters
-
Portsmouth、Virginia、アメリカ、23708-2197
- Naval Medical Center - Portsmouth
-
Richmond、Virginia、アメリカ、23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke、Virginia、アメリカ、24014
- Carilion Children's
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- Seattle Children's Hospital
-
Spokane、Washington、アメリカ、99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma、Washington、アメリカ、98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma、Washington、アメリカ、98431
- Madigan Army Medical Center
-
-
West Virginia
-
Huntington、West Virginia、アメリカ、25701
- Edwards Comprehensive Cancer Center
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Green Bay、Wisconsin、アメリカ、54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield、Wisconsin、アメリカ、54449
- Marshfield Medical Center-Marshfield
-
Milwaukee、Wisconsin、アメリカ、53226
- Children's Hospital of Wisconsin
-
-
-
-
Central District
-
Petah Tikva、Central District、イスラエル、4920235
- Schneider Children's Medical Center of Israel
-
-
-
-
-
Monza、イタリア、20900
- Clinica Pediatrica Università Milano-Bicocca Ospedale S. Gerardo/Fondazione MBBM
-
-
-
-
-
Utrecht、オランダ、3584 CT
- Princess Máxima Center for Pediatric Oncology
-
-
-
-
New South Wales
-
Hunter Regional Mail Centre、New South Wales、オーストラリア、2310
- John Hunter Children's Hospital
-
Randwick、New South Wales、オーストラリア、2031
- Sydney Children's Hospital
-
Westmead、New South Wales、オーストラリア、2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane、Queensland、オーストラリア、4101
- Queensland Children's Hospital
-
-
Western Australia
-
Perth、Western Australia、オーストラリア、6008
- Princess Margaret Hospital for Children
-
Perth、Western Australia、オーストラリア、6009
- Perth Children's Hospital
-
-
-
-
-
Vienna、オーストリア、1090
- St. Anna Children's Hospital
-
-
-
-
-
Québec、カナダ、G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Calgary、Alberta、カナダ、T3B 6A8
- Alberta Children's Hospital
-
Edmonton、Alberta、カナダ、T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston、Ontario、カナダ、K7L 2V7
- Kingston Health Sciences Centre
-
London、Ontario、カナダ、N6A 5W9
- Children's Hospital
-
Ottawa、Ontario、カナダ、K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto、Ontario、カナダ、M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal、Quebec、カナダ、H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal、Quebec、カナダ、H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke、Quebec、カナダ、J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Saskatoon、Saskatchewan、カナダ、S7N 4H4
- Saskatoon Cancer Centre
-
Saskatoon、Saskatchewan、カナダ、S7N 0W8
- Jim Pattison Children's Hospital
-
-
-
-
-
Riyadh、サウジアラビア、11211
- King Faisal Specialist Hospital and Research Centre
-
-
-
-
-
Zurich、スイス、CH8032
- University Children's Hospital
-
-
-
-
Skåne County
-
Lund、Skåne County、スウェーデン、22185
- Skane University Hospital
-
-
-
-
-
Prague、チェコ、15018, 5-Motol
- University Hospital Motol
-
-
-
-
-
Santiago、チリ
- Hospital Roberto del Rio-Universidad de Chile
-
-
-
-
-
Hamburg、ドイツ、20246
- Universitätsklinik Eppendorf
-
-
Schleswig-Holstein
-
Kiel、Schleswig-Holstein、ドイツ、24105
- University Medical Center chleswig- Campus Kiel
-
-
-
-
-
Christchurch、ニュージーランド、8011
- Christchurch Hospital
-
-
Auckland
-
Grafton、Auckland、ニュージーランド、1145
- Starship Children's Hospital
-
-
-
-
-
Tampere、フィンランド、33521
- Tampere University Hospital
-
-
-
-
-
Rennes、フランス、35203
- CHU Hopital Sud
-
-
-
-
-
Caguas、プエルトリコ、00726
- HIMA San Pablo Oncologic Hospital
-
San Juan、プエルトリコ、00926
- University Pediatric Hospital
-
San Juan、プエルトリコ、00912
- San Jorge Children's Hospital
-
-
-
-
Flemish Brabant
-
Leuven、Flemish Brabant、ベルギー、3000
- Hospitals Leuven
-
-
-
-
Kowloon
-
Kowloon Bay、Kowloon、香港
- Hong Kong Children's Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
For patients enrolled on APEC14B1 prior to enrollment on AALL1631, the required diagnostic bone marrow sample has been fulfilled
- For patients who have not previously enrolled on APEC14B1 prior to enrollment on AALL1631, a baseline diagnostic sample (or peripheral blood sample with blasts if marrow sample unavailable) must be available to develop an MRD probe
- In addition, laboratory reports detailing evidence of BCR::ABL1 fusion or ABL-class fusion must be submitted for rapid central review within 72 hours of study enrollment
-
>= 1 year (365 days) and =< 21 years at ALL diagnosis
-
Ph+ (BCR::ABL1 fusion): newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed phenotypic acute leukemia (MPAL meeting 2016 World Health Organization [WHO] definition) with definitive evidence of BCR::ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or molecular methodologies
-
ABL-class fusion: newly diagnosed B-ALL with definitive evidence of ABL-class fusions. ABL-class fusions are defined as those involving the following genes: ABL1, ABL2, CSF1R, PDGFRB, PDGFRA. Methods of detection include fluorescence in-situ hybridization ([FISH], e.g. using break-apart or colocalization signals probes), multiplex or singleplex reverse-transcription polymerase chain reaction (RT-PCR), whole transcriptome or panel-based RNA-sequencing (e.g. TruSight RNA Pan-Cancer Panel; Illumina, San Diego, California [CA], United States of America [USA] or similar)
-
Ph+ patients must have previously started Induction therapy, which includes vincristine, a corticosteroid, pegaspargase, with or without anthracycline, and/or other standard cytotoxic chemotherapy
-
Ph+ patients have not received more than 14 days of multiagent Induction therapy beginning with the first dose of vinCRIStine
-
Ph+ patients may have started imatinib prior to study entry but have not received more than 14 days of imatinib
-
ABL-class fusion patients must have previously completed the 4 or 5 weeks of multiagent Induction chemotherapy (Induction IA phase)
-
ABL-class fusion patients may have started imatinib during Induction IA, at the same time of or after the first vinCRIStine dose
-
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2
-
Direct bilirubin =< 2.0 mg/dL
-
Shortening fraction of >= 27% by echocardiogram
-
Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
-
Corrected QT interval, QTc < 480 msec
- Note: Repeat echocardiogram and electrocardiogram are not required if they were performed at or after initial ALL diagnosis, before study enrollment
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine within normal limits based on age/gender, as follows:
- 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)
- 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)
- 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)
- 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)
- 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)
- >= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)
Exclusion Criteria:
-
Known history of chronic myelogenous leukemia (CML)
-
ALL developing after a previous cancer treated with cytotoxic chemotherapy
-
Active, uncontrolled infection, or active systemic illness that requires ongoing vasopressor support or mechanical ventilation
-
Down syndrome
-
Pregnancy and breast feeding
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of treatment according to protocol
-
Patients with congenital long QT syndrome, history of ventricular arrhythmias or heart block
-
Prior treatment with dasatinib, or any TKI other than imatinib
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A (imatinib mesylate, EsPhALL chemotherapy)
See Detailed Description |
Correlative studies Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Ancillary studies Given IV
他の名前:
Given IV
他の名前:
Given PO
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given PO or IV
他の名前:
Given IT
他の名前:
Given IV, SC, or IT
他の名前:
Given PO or IV
他の名前:
Given IV
他の名前:
Given SC or IV
他の名前:
Given PO
他の名前:
Given PO or IV
他の名前:
Given IV
他の名前:
Given PO
他の名前:
Given IT
他の名前:
Given PO
他の名前:
|
|
実験的:Arm B (imatinib mesylate, COG/BFM chemotherapy)
See Detailed Description. |
Correlative studies Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Ancillary studies Given PO
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given PO or IV
他の名前:
Given IT
他の名前:
Given IV, SC, or IT
他の名前:
Given PO or IV
他の名前:
Given IV
他の名前:
Given PO
他の名前:
Given PO or IV
他の名前:
Given IV
他の名前:
Given PO
他の名前:
Given PO
他の名前:
|
|
実験的:Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)
See Detailed Description |
Correlative studies Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Ancillary studies Given IV
他の名前:
Given IV
他の名前:
Given PO
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Given PO or IV
他の名前:
Given IT
他の名前:
Given IV, SC, or IT
他の名前:
Given PO or IV
他の名前:
Given IV
他の名前:
Given SC or IV
他の名前:
Given PO
他の名前:
Given PO or IV
他の名前:
Given IV
他の名前:
Given PO
他の名前:
Given IT
他の名前:
Given PO
他の名前:
Undergo HSCT
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)
時間枠:Up to 3 years
|
Three-year DFS and 95% confidence intervals (CI) of SR Ph+ ALL patients treated continuous imatinib mesylate with high risk Children's Oncology Group (COG)-ALL chemotherapy backbone or more intensive European (Es)PhALL chemotherapy backbone. |
Up to 3 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
DFS on Randomized Arms (SR Ph+ ALL and ABL-class fusion positive patients)
時間枠:Up to 3 years
|
Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric Ph+ and ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
Feasibility of post hematopoietic stem cell transplantation (HSCT) imatinib mesylate administration after allogenic HSCT in high risk Ph+ ALL patients
時間枠:Up to 2 years
|
The proportion of patients who receive at least 75% of intended doses. |
Up to 2 years
|
|
Event free survival (EFS) of high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate
時間枠:Up to 3 years
|
Three-year EFS and 95% CI for high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate. EFS is defined as the time from the date of bone marrow for minimal residual disease (MRD) assessment at end-IB to first event (resistant disease [MRD >= 10-2 or morphologic residual disease at end of consolidation block 3], relapse, progressive disease [i.e., MRD >= 10-2 at two post-HSCT time points separated by at least 2 weeks], second malignancy, or death in complete remission), or time to last follow-up for patients without events. |
Up to 3 years
|
|
Incidence of grade 3 or higher infections in standard risk Ph+ ALL patients in the two randomized arms
時間枠:Up to 3 years
|
Evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The rate of infections during the post IB/pre-maintenance phases of treatment will be described for each randomization group. |
Up to 3 years
|
|
EFS of all Ph+ patients
時間枠:Up to 3 years
|
Three-year EFS and 95% CI for Ph+ ALL patients. EFS here is defined as the time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignant, or death, whichever occurs first. |
Up to 3 years
|
|
Overall survival (OS) of all Ph+ patients
時間枠:Up to 3 years
|
Three-year OS and 95% CI for Ph+ ALL patients. OS is defined as the time from study enrollment to death from any cause. |
Up to 3 years
|
|
OS of SR Ph+ patients
時間枠:Up to 3 years
|
Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients |
Up to 3 years
|
|
OS of SR Ph+ patients by randomization group
時間枠:Up to 3 years
|
Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients by randomization group: treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
OS of high risk Ph+ patients
時間枠:Up to 3 years
|
Three-year OS (time from the date of MRD assessment at end-IB to death from any cause) and 95% CI of HR pediatric Ph+ patients. |
Up to 3 years
|
|
EFS of all eligibility ABL-class fusion positive ALL patients
時間枠:Up to 3 years
|
Three-year EFS (time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignancy, or death, whichever occurs first) and 95% CI of ABL-class fusion positive patients. |
Up to 3 years
|
|
OS of all eligibility ABL-class fusion positive ALL patients
時間枠:Up to 3 years
|
Three-year OS (the time from study enrollment to death from any cause) and 95% CI of ABL-class fusion positive patients. |
Up to 3 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of toxicities associated with post-HSCT administration of imatinib mesylate
時間枠:Up to 2 years
|
Evaluated according to NCI CTCAE version 5.0. Frequencies of target toxicities in high risk patients after the initiation of post-HSCT imatinib mesylate will be described. For the high risk patients, the specific targeted toxicities will include grade 4 neutropenia, grade 4 thrombocytopenia, grade 3 or higher bilirubin, grade 4 or higher transaminitis, and grade 3 or higher infection. |
Up to 2 years
|
|
Incidence of long-term toxicities in patients treated with chemotherapy plus imatinib mesylate (no transplant) in both arms
時間枠:Up to 3 years
|
Evaluated according to NCI CTCAE version 5.0. Frequencies of long-term toxicities will be described and differences between randomized arms will be explored. Specific long-term toxicities to be explored include cardiac (echocardiographic abnormalities, including decreased left ventricular (LV) function and decreased LV wall thickness), growth (linear height, bone age), and second malignant neoplasm. |
Up to 3 years
|
|
MRD measured by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) and next generation sequencing (NGS) assay
時間枠:Up to 6 months
|
For all patients, frequencies and prognostic significance (DFS, EFS, OS) will be explored for MRD levels (i.e., MRD negative, detectable at < 5 x 10^-4, and dectectable at >= 5 x 10^-4) at end of Induction IB. |
Up to 6 months
|
|
MRD in high risk Ph+ patients measured by IGH-TCR PCR and NGS assay
時間枠:Up to 3 years
|
The outcome of high risk Ph+ patients will be described, including proportion of patients who achieve MRD-negativity just prior to HSCT, and at regular intervals post-HSCT. Associations between these findings and long-term outcomes (e.g., OS, DFS) will be explored. |
Up to 3 years
|
|
MRD assessments made by IGH-TCR PCR assay and NGS assay
時間枠:Up to 3 years
|
Concordance of MRD assessments made by IGH-TCR PCR assay and NGS assay will be described and evaluated. Scatter plots and diagrams will be used to examine agreements and patterns of agreement or any differences found. Concordance will be explored both for the overall cohort, as well as by risk group. The increased sensitivity of the NGS will be closely examined to find cases where the MRD levels are detectable by NGS but undetectable by PCR, as well as cases in which one test yields results and the other does not (test failure). Prognostic relationships on outcomes for these subjects will be inspected. |
Up to 3 years
|
|
IKZF1 deletions alone
時間枠:Up to 3 years
|
Will determine and validate if IKZF1 deletions alone predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
IKZF1 deletions with other transcription factor deletions
時間枠:Up to 3 years
|
Will determine and validate if IKZF1 deletions with other transcription factor deletions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
Other identified genetic lesions
時間枠:Up to 3 years
|
Will determine and validate if other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
Frequency of p190 and p210 BCR::ABL1 fusion variants
時間枠:Up to 3 years
|
For both standard risk and high risk groups, frequencies and prognostic significance (OS, DFS) will be explored for p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL. |
Up to 3 years
|
|
Adherence to oral chemotherapeutic agents in standard risk Ph+ ALL patients
時間枠:Up to 2 years
|
Adherence to imatinib mesylate, 6-mercaptopurine, and methotrexate will be evaluated in COG-enrolled participants using an electronic monitoring device. Adherence rate will be computed for each month of adherence monitoring. Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6-mercaptopurine (6MP), and methotrexate dose-intensity. |
Up to 2 years
|
|
Adherence to imatinib mesylate after allogeneic HSCT in high risk Ph+ ALL patients
時間枠:Up to 2 years
|
Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6MP, and methotrexate dose-intensity. |
Up to 2 years
|
|
DFS of SR ABL-class fusion positive patients
時間枠:Up to 3 years
|
Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
Secondary and exploratory aims applied to ABL-class fusion positive patients
時間枠:Up to 3 years
|
Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients. |
Up to 3 years
|
|
Therapeutic impact of major secondary events
時間枠:Up to 3 years
|
Will determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events. |
Up to 3 years
|
|
Secondary and exploratory aims applied to super-set of Ph+ and ABL-class fusion positive patients
時間枠:Up to 3 years
|
Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in the superset of Ph+ and ABL-class fusion positive ALL patients. |
Up to 3 years
|
|
In vivo activity
時間枠:Up to 3 years
|
Will test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631. |
Up to 3 years
|
|
Molecular heterogeneity
時間枠:Up to 3 years
|
Will decipher the molecular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays. |
Up to 3 years
|
|
Cellular heterogeneity
時間枠:Up to 3 years
|
Will decipher the cellular heterogeneity of CML-like versus typical Ph+ ALL via single-cell genomics and functional assays. |
Up to 3 years
|
|
CML-like phenotypes
時間枠:Up to 3 years
|
Will investigate CML-like phenotypes via single-cell ribonucleic acid and deoxyribonucleic acid sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions. |
Up to 3 years
|
協力者と研究者
捜査官
- 主任研究者:Lewis B Silverman、Children's Oncology Group
- 主任研究者:Andrea Biondi、EsPhALL Network/ BFM Study Group
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 新生物
- 免疫系疾患
- 感染症
- ウイルス病
- 組織型別の新生物
- 血液疾患
- DNAウイルス感染症
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- リンパ腫、非ホジキン
- リンパ腫、B細胞
- リンパ腫
- 白血病、リンパ
- 白血病
- エプスタイン-バーウイルス感染症
- ヘルペスウイルス感染症
- 腫瘍ウイルス感染症
- ヘミックおよびリンパ疾患
- 前駆細胞リンパ芽球性白血病-リンパ腫
- バーキットリンパ腫
- 前駆T細胞リンパ芽球性白血病-リンパ腫
- 白血病、二表現型、急性
- ホルモン
- ホルモン、ホルモン代替品、ホルモン拮抗薬
- ペプチド
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 硫黄化合物
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 治療
- 外科的処置、手術
- 核酸、ヌクレオチド、およびヌクレオシド
- 炭化水素
- 炭化水素、周期的
- 生物学的要因
- 炭水化物
- カルボン酸
- アルカロイド
- ポドフィロトキシン
- テトラヒドロノフタレン
- ナフタレン
- 多環芳香族炭化水素
- 炭化水素、芳香
- 多環式化合物
- グルコシド
- グリコシド
- 移植
- アミド
- ヒドロラーゼ
- 酵素
- 酵素と補酵素
- インドール
- プリン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- 妊娠
- 妊娠
- ステロイド
- 融合リング化合物
- ステロイド、フッ素化
- ベンゼン誘導体
- スルホン酸
- 硫酸
- ホスホルアミドマスタード
- 窒素マスタード化合物
- マスタード化合物
- 炭化水素、ハロゲン化
- ホスホラミド
- 有機リン化合物
- ヌクレオシド
- ホルミルテトラヒドロフォレート
- テトラヒドロフォレート
- 葉酸
- 羽毛
- プテリジン
- 細胞間シグナル伝達ペプチドとタンパク質
- 妊娠症
- アミドヒドロラーゼ
- ヴィンカアルカロイド
- セコロガニントリプタミンアルカロイド
- インドールアルカロイド
- インドリジジン
- インドリジン
- アラビノヌクレオシド
- アミノプテリン
- アントラサイクリン
- ナフテセン
- アミノグリコシド
- コエンザイム
- 糖タンパク質
- グリココンジュゲート
- 妊娠
- 妊娠
- 細胞移植
- 細胞および組織ベースの治療
- 生物療法
- 11-ヒドロキシコルチコステロイド
- ヒドロキシコルチコステロイド
- 副腎皮質ホルモン
- 17-ヒドロキシコルチコステロイド
- オキサジン
- 酸、炭素環
- ベンゼンスルホン酸塩
- アリルスルホン酸塩
- アリールスルホン酸
- ベンゾエート
- コロニー刺激因子
- 造血細胞成長因子
- サイトカイン
- ベンザミド
- ピペラジン
- スルフヒドリル化合物
- ディケットピペラジン
- メシル酸イマチニブ
- デキサメタゾン
- メトトレキサート
- プレドニゾロン
- シクロホスファミド
- シタラビン
- エトポシド
- ロイコボリン
- レボルイコボリン
- ドキソルビシン
- ビンクリスチン
- メチルプレドニゾロン
- ダウノルビシン
- ヒドロコルチゾン
- アスパラギナーゼ
- メルカプトプリン
- デクスラゾキサン
- ラゾキサン
- チオグアニン
- イホスファミド
- ドベシル酸カルシウム
- 幹細胞移植
- デキサメタゾン21-リン酸
- 顆粒球コロニー刺激因子
- Filgrastim
- CALASPARGASE PEGOL
- アザチオプリン
- メルフォス
- Pegaspargase
- Auricularum
- デキサメタゾン酢酸
- exifone
- Medrol Veriderm
その他の研究ID番号
- AALL1631
- U10CA180886 (米国 NIH グラント/契約)
- 2017 (米国 NIH グラント/契約)
- AALL1631 (その他の識別子:CTEP)
- NCI-2016-01588 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- 2017-000705-20
- 2024-515499-12-00
- AALL1631 (その他の識別子:Children's Oncology Group)
- 2017-000705-20 (EudraCT番号)
- 2024-515499-12-00 (Ctis)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。